Flucytosine

Mechanism of Action - Fungal DNA Faker

• Selective Uptake: Enters fungal cells via cytosine-specific permease.
• Lethal Conversion: Inside the fungus, it's converted to its active forms.

• DNA Block: 5-FdUMP inhibits thymidylate synthase, blocking dTMP synthesis and halting DNA production.
• RNA Disruption: 5-FUTP is incorporated into fungal RNA, disrupting protein synthesis.

⭐ Selective Toxicity: Human cells lack cytosine deaminase, preventing the conversion of Flucytosine to toxic 5-FU, which is a key reason for its antifungal selectivity.

📌 Mnemonic: Flucytosine → Fake Uracil → Faulty DNA/RNA.

Clinical Spectrum & Use - The Amphotericin Ally

• Narrow-spectrum fungistatic; resistance develops rapidly when used as monotherapy.
• Primary Targets:
  • Cryptococcus neoformans
  • Some Candida spp.
  • Molds causing chromoblastomycosis.
• Key Strategy: Used synergistically with Amphotericin B.
  • Amphotericin B creates pores in the fungal membrane, which ↑ flucytosine entry.
  • This combination allows for lower, less toxic doses of Amphotericin B.
• Main Indication:
  • Severe systemic infections, particularly cryptococcal meningitis.

⭐ The synergy is key: Amphotericin B opens the "door" (cell membrane pores), letting Flucytosine enter the fungal cell to inhibit DNA/RNA synthesis.

Pharmacokinetics - Body's Drug Tour

• Absorption: Well-absorbed orally (>90% bioavailability).
• Distribution:
  • Distributes widely into body tissues and fluids.
  • Excellent penetration into the CSF (~75% of serum levels).
  • Low plasma protein binding.
• Metabolism: Minimal host metabolism. Gut flora can convert it to 5-fluorouracil (5-FU), contributing to toxicity.
• Excretion:
  • Primarily renal; >90% excreted unchanged in urine.
  • ⚠️ Dose reduction is critical in renal insufficiency.

⭐ Its ability to penetrate the CNS makes it vital for treating fungal meningitis, especially cryptococcal, typically in combination with Amphotericin B.

Adverse Effects - Bone Marrow Blues

• Primary Toxicity: Dose-dependent bone marrow suppression.
• Mechanism: Intestinal flora convert flucytosine to the antimetabolite 5-fluorouracil (5-FU), a potent myelosuppressant.
  • Inhibits thymidylate synthase, disrupting DNA and RNA synthesis in hematopoietic stem cells.
• Manifestations:
  • Anemia (↓ RBCs)
  • Leukopenia (↓ WBCs) → risk of infection
  • Thrombocytopenia (↓ Platelets) → risk of bleeding

⭐ High-Yield: Toxicity is markedly increased in patients with renal insufficiency due to drug accumulation. Always monitor plasma levels and renal function.

Resistance - Fungal Escape Plan

• Altered uptake: Mutation in fungal cytosine permease reduces drug entry.
• Impaired metabolism: Deficient cytosine deaminase or UMP pyrophosphorylase prevents conversion to active metabolites (5-FU, FdUMP).

⭐ Resistance develops rapidly with monotherapy. Always combine, usually with Amphotericin B for synergistic effect.

High‑Yield Points - ⚡ Biggest Takeaways

• Converted to 5-fluorouracil (5-FU) in fungal cells, which inhibits DNA and RNA synthesis by blocking thymidylate synthase.
• Almost always used in combination with Amphotericin B, especially for severe systemic mycoses like cryptococcal meningitis.
• Amphotericin B enhances flucytosine uptake into fungal cells, creating a synergistic effect.
• Rapid resistance develops when used as monotherapy.
• Main adverse effect is bone marrow suppression due to systemic conversion to 5-FU.